Study Trends Online Professional Activities and Reveals Specialty-specific Marketing Opportunities

Manhattan ResearchManhattan Research, a healthcare market research services firm, announced the leading pharmaceutical product website destinations for physicians from its new physician research study, "ePharma Physician® v7.0: The Future of Professional eMarketing.". Manhattan Research recently hosted a webcast discussing highlights of the ePharma Physician® v7.0 research.

Top 10 Pharma Product Websites Among Physicians in 2007
Ranked by Number of U.S. Primary Care Physician Visitors

1 Januvia
2 Singulair
3 Advair
4 Chantix
5 Adderall XR
6 Byetta
7 Gardasil
8 Vytorin
9 Avandia
10 Concerta

Source: ePharma Physician® v7.0, Manhattan Research, LLC

"The latest research reveals physician site traffic is spread among product sites of new and early launch stage treatments, those with clinical news coverage, and consistent with years past, products with a significant consumer advertising component," states Mark Bard, president of Manhattan Research. He continues, "We have seen these product sites evolve into brand gateways with visitation from physicians, healthcare professionals, and consumers and with the majority of the top 10 product sites changing from year to year, there is clearly a need among physicians for the most upto- date product information."

For the sixth consecutive year, Manhattan Research has determined the leading online physician destinations based on the number of physician visitors as well as the content satisfaction of those who visit. In-depth analysis of top product and corporate pharmaceutical websites, health portals, online journal sites, specialty-specific sites, newsletters and society sites is now available as part of the ePharma Physician® v7.0 advisory service.

ePharma Physician® v7.0 reveals the relevant market share and physician satisfaction for 300+ leading pharmaceutical product websites. A complete list of available product sites is available at www.manhattanresearch.com/ePP.aspx

ePharma Physician® v7.0 also includes the following specialist segments in the research: Allergy and Immunology, Cardiology (Cardiovascular Surgery and Interventional Cardiology), Dermatology, Emergency Medicine, Endocrinology, Family Medicine/General Practice, Gastroenterology, Infectious Disease or HIV physician, Internal Medicine, Nephrology, Neurology, OB/GYN, Oncology–Hematology & Hematology, Ophthalmology, Pediatrics, Psychiatry, Pulmonology, Radiology, Rheumatology, Surgery (General and Orthopedic), and Urology.

About Manhattan Research
In addition to ePharma Physician®, Manhattan Research conducts numerous research studies among physicians and consumers in the United States and in Europe. Each study serves a unique purpose and focuses on different aspects of information technology adoption. Broad research is complemented by targeted analysis among more than 50 consumer therapeutic segments and 25 physician specialist segments. For further information, please visit www.manhattanresearch.com

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]